Caution over monoclonal antibody treatment for MS

http://ifttt.com/images/no_image_card.png Alemtuzumab, an anti-CD52 monoclonal antibody, provides a more effective treatment for individuals with relapsing‑remitting multiple sclerosis than the immunomodulating drug interferon beta 1a, but has significant side effects, show findings from a phase III trial.

Read more...